You are here

Selumetinib Fails to Improve Survival in Lung Cancer Study

Phase 3 trial evaluates selumetinib/docetaxel combo

AstraZeneca has announced the results from a phase 3 trial of selumetinib, a MEK 1/2 inhibitor, in combination with docetaxel chemotherapy as second-line treatment in patients with KRAS mutation-positive (KRASm) locally advanced or metastatic non–small-cell lung cancer (NSCLC).

The study did not meet its primary endpoint of progression-free survival (PFS), and selumetinib did not have a significant effect on overall survival (OS).

MEK 1 and MEK 2 are critical components of the RAS–ERK pathway, the activation of which is implicated in driving cancer growth and progression, including in patients with KRASm NSCLC.

SELECT-1 was a double-blind, randomized, placebo-controlled trial designed to assess the efficacy and safety of selumetinib (75 mg twice daily, administered orally on a continuous schedule) in combination with docetaxel (75 mg/m2 intravenously on day 1 of every 21-day cycle) compared with matched placebo in combination with docetaxel (same schedule) in 510 patients receiving second-line treatment for KRASm locally advanced or metastatic NSCLC (stage IIIB–IV), confirmed by central testing of tumor tissue using the Cobas KRAS mutation test (Roche Molecular Systems).

In May 2016, the FDA granted an orphan drug designation to selumetinib for adjuvant treatment of patients with stage III or stage IV differentiated thyroid cancer. The medication is being explored in that setting, as well as in patients with neurofibromatosis type 1, a genetic disorder that causes tumors to grow along nerve tissue.

Source: AstraZeneca; August 9, 2016.

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
National Statistics Report Factors In Race, Ethnicity for the First Time